Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.67 |
| ▸ | TDO2 | P48775 | 3/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983658 | 0.87 | IDO1 (0.61) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL20340870 | 0.84 | IDO1 (0.63) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL25762243 | 0.83 | IDO1 (0.70) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL25762241 | 0.82 | IDO1 (0.72) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL20340874 | 0.81 | IDO1 (0.56) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL9120585 | 0.81 | IDO1 (0.63) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL25564665 | 0.81 | IDO1 (0.63) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL24740358 | 0.80 | IDO1 (1.00) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL5528789 | 0.80 | IDO1 (1.00) | IDO1TDO2GSK3BMAPTKDM4E | |
| SCHEMBL31265741 | 0.80 | IDO1 (1.00) | IDO1TDO2GSK3BMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683335-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-06-16 | — | — | US | disclosed |
| US-10011643-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | ASAHI KASEI PHARMA CORPORATION (JP) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011643-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | PTH1R, PTMS, VIP | IDO1 4715/4885TDO2 4359/4885GSK3B 4286/4885 |
| US-10683335-B2 | Freeze-dried preparation containing high-purity PTH and method for producing same | PTH1R, PTMS, VIP | IDO1 4780/4885TDO2 4605/4885GSK3B 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.